SCHEMBL3625972

SCHEMBL3625972

CS(=O)(=O)NC(=O)c1ccc2c(c1)c1c(=O)[nH]ccc1c1[nH]c(C3CCCC3)nc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.38
JAK1 P23458 3/20 0.38
GSK3B P49841 2/20 0.37
CHEK1 O14757 2/20 0.37
MAPK14 Q16539 2/20 0.37
TYK2 P29597 2/20 0.37
JAK3 P52333 2/20 0.37
IKBKB O14920 1/20 0.37
MAPK13 O15264 1/20 0.37
DAPK3 O43293 1/20 0.37
PRKD3 O94806 1/20 0.37
FYN P06241 1/20 0.37
RET P07949 1/20 0.37
HCK P08631 1/20 0.37
PDGFRB P09619 1/20 0.37
PIM1 P11309 1/20 0.37
FGFR1 P11362 1/20 0.37
PDGFRA P16234 1/20 0.37
PRKCA P17252 1/20 0.37
PRKACA P17612 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14373980 0.84 CHEK1 (0.40) JAK2JAK1GSK3BCHEK1MAPK14
SCHEMBL3619318 0.83 CHEK1 (0.51) JAK2CHEK1PBKADORA1ADORA2A
SCHEMBL3622445 0.83 ALDH1A1 (0.41) JAK2JAK1GSK3BCHEK1MAPK14
SCHEMBL3617138 0.82 IMPDH2 (0.42) JAK2CHEK1RETFLT1MAPK3
SCHEMBL4458883 0.82 RAB9A (0.42) GSK3BMAPK14RPS6KA3
SCHEMBL3618943 0.80 HPGD (0.43) JAK2JAK1CHEK1MAPK14TYK2
SCHEMBL3611406 0.80 MAP3K7 (0.40) JAK2JAK1CHEK1MAPK14TYK2
SCHEMBL3620214 0.80 HTR2B (0.40) JAK2JAK1CHEK1MAPK14TYK2
SCHEMBL3622686 0.80 RAB9A (0.47) JAK2MAPK1
SCHEMBL3613483 0.79 PARP1 (0.42) CHEK1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032141-B1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME (US) 2012-10-31 EP claimed
US-20090306071-A1 Inhibitors of Janus Kinases MERCK SHARP & DOHME LLC 2009-12-10 US claimed
EP-2032141-B1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME (US) 2012-10-31 EP disclosed
US-7763634-B2 Inhibitors of janus kinases MERCK & CO., INC. (US) 2010-07-27 US disclosed
US-20090306071-A1 Inhibitors of Janus Kinases MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306071-A1 Inhibitors of Janus Kinases JAK2, JAK3, JAK1 JAK2 1/4885JAK1 3/4885GSK3B 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.